Close this search box.

Ardena and RiboPro Forge Strategic Alliance

RIBOPRO is joining forces with Ardena, a leading CDMO in the nanomedicine field, recognizing the power the unique combination of products and services this alliance can offer to RNA therapy pioneers. This alliance signals the start of a new phase for RIBOPRO, one marked with an expanding global reach and accelerated development of our portfolio of advanced mRNA and LNP technologies and services.

Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RIBOPRO to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry.

The new alliance combines Ardena’s expertise in custom development and cGMP manufacturing of lipids and LNP-mRNA formulations with RIBOPRO’s proprietary portfolio of mRNA-related technologies and experience in mRNA synthesis and encapsulation.

This will offer a unique end-to-end solution for advanced mRNA and lipid nanoparticles (LNP) production, enabling drug developers to develop faster and with a substantially lower scaling and manufacturing risk. The well-matched processes of the partners also alleviates costly and time-intensive tech-transfer steps.

mRNA represents a fast-emerging class of biotherapeutics, and the potential for mRNA technology to transform global healthcare is significant. However, the global expertise and capabilities necessary to produce cGMP grade mRNA and its encapsulation in LNP are currently limited.

Ardena CEO Harry Christiaens said: “The availability of high-quality, stable, and non-immunogenic mRNA in combination with the formulation, process development, analytical development, and manufacturing capabilities of various LNP compositions is critical to achieving the desired payload, encapsulation, stability in circulation, in vivo transfection, and tissue-specific delivery.

“By having all the expertise at the same table, the quality of the new therapeutic and its development plan will be higher from the start, maximizing chances of positively impacting the patient.”

“The Ardena/RIBOPRO alliance will be a science-led and service-strong partnership covering the entire CDMO supply chain from advanced mRNA synthesis to aseptic fill and finishing.

“In a highly competitive niche area of the mRNA/LNP market, the Ardena/RIBOPRO alliance aspires to differentiate itself from the competition through its fully integrated, highly customer-centric approach. The combination of a state-of-the-art proprietary portfolio of mRNA and LNP technologies with over a decade of nanomedicine development expertise offers our customers an equally unique and beneficial service resulting in accelerated drug development programs.”

“The strategic alliance with Ardena represents an exciting opportunity for RIBOPRO,” said Sander van Asbeck, CEO of RIBOPRO. “Our portfolio of proprietary technologies, and expertise in mRNA synthesis and encapsulation, combined with Ardena’s experience in process development and cGMP manufacturing, will provide our clients with a seamless pathway to advanced mRNA therapeutics with the ultimate goal of getting innovative medicines to patients sooner. Our collaboration will also help RiboPro develop a deeper understanding of customer needs and create even more advanced mRNA and LNP solutions accordingly.”

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.